Ospedali Riuniti, Bergamo, Italy.
Crit Rev Oncol Hematol. 2010 May;74(2):106-33. doi: 10.1016/j.critrevonc.2010.01.010.
Colon cancer is one of the leading tumours in the world and it is considered among the big killers, together with lung, prostate and breast cancer. In the recent years very important advances occurred in the field of treatment of this frequent disease: adjuvant chemotherapy was demonstrated to be effective, chiefly in stage III patients, and surgery was optimized in order to achieve the best results with a low morbidity. Several new target-oriented drugs are under evaluation and some of them (cetuximab and bevacizumab) have already exhibited a good activity/efficacy, mainly in combination with chemotherapy. The development of updated recommendations for the best management of these patients is crucial in order to obtain the best results, not only in clinical research but also in every-day practice. This report summarizes the most important achievements in this field and provides the readers useful suggestions for their professional practice.
结肠癌是全球主要肿瘤之一，与肺癌、前列腺癌和乳腺癌一起被视为“致命杀手”之一。近年来，在这种常见疾病的治疗领域取得了非常重要的进展：辅助化疗已被证明有效，主要在 III 期患者中，并且为了实现低发病率的最佳效果，手术也得到了优化。几种新的靶向药物正在评估中，其中一些（西妥昔单抗和贝伐单抗）已经表现出良好的活性/疗效，主要与化疗联合使用。为了获得最佳结果，不仅在临床研究中，而且在日常实践中，制定这些患者最佳管理的更新建议至关重要。本报告总结了该领域的最重要成果，并为读者提供了在专业实践中有用的建议。
